scholarly journals Optilume® drug-coated balloon dilation in complex female urethral stricture

2021 ◽  
pp. 101987
Author(s):  
Jannik Stuehmeier ◽  
Lukas Andrius Jelisejevas ◽  
Patricia Kink ◽  
Alexandra Gulacsi ◽  
Wolfgang Horninger ◽  
...  
Keyword(s):  
Urethral Stricture ◽  
Balloon Dilation ◽  
Drug Coated Balloon ◽  
Female Urethral Stricture

scholarly journals A drug-coated balloon treatment for urethral stricture disease: Interim results from the ROBUST I study

2020 ◽  
Vol 14 (6) ◽  
Author(s):  
Ramon Virasoro ◽  
Jessica DeLong ◽  
Rachel Mann ◽  
Rafael Estrella ◽  
Merycarla Pichardo ◽  
...  
Keyword(s):  
Urethral Stricture ◽  
Balloon Dilation ◽  
Serious Adverse Events ◽  
Urethral Strictures ◽  
Safety Endpoint ◽  
Study Population ◽  
Study Sites ◽  
One Year ◽  
Drug Coated Balloon ◽  
Anatomic Success

Introduction: We aimed to investigate the safety and preliminary efficacy of the OptilumeTM paclitaxel-coated balloon for the treatment of recurrent urethral stricture. Methods: Men with bulbar urethral strictures ≤2 cm with 1–4 prior endoscopic treatments were enrolled at four study sites after Ethics Committee approvals. All subjects were treated with mechanical balloon dilation or direct visualization internal urethrotomy prior to drug-coated balloon treatment. Patients were evaluated at 2–5 days, 14 days, three, six, and 12-months post-treatment. The primary safety endpoint was serious complications through 90 days post-procedure. The preliminary efficacy endpoint was anatomic success, defined as urethral lumen ≥14 Fr at 12 months. Results: A total of 53 subjects were enrolled and treated; 46 completed the 12-month followup. Forty-three percent of men had undergone >1 previous dilation; the mean for the overall study population was 1.7 prior dilations. There were no serious adverse events related to the treatment within 90 days. Anatomic success was achieved in 32/46 (70%; 95% confidence interval [CI] 54–82%) at 12 months. The 14 failures included seven cystoscopic recurrences, five retreatments, and two patients who exited the study early due to symptom recurrence. Conclusions: One-year data indicates the OptilumeTM paclitaxel-coated balloon is safe for the treatment of recurrent bulbar urethral strictures. Early efficacy results are encouraging and support further followup of these men through five years, as well as further investigation with a randomized trial.

Outcome of dorsal buccal graft urethroplasty in female urethral stricture disease (FUSD); our institutional experience

2021 ◽  
Author(s):  
Abdul Rouf Khawaja ◽  
Yaser Ahmad Dar ◽  
Farzana Bashir ◽  
Prince Muzafer Wani ◽  
Arif Hamid Bhat ◽  
...  
Keyword(s):  
Urethral Stricture ◽  
Urethral Stricture Disease ◽  
Institutional Experience ◽  
Female Urethral Stricture

Assessment of a new transurethral balloon dilation catheter in the treatment of urethral stricture disease

Urology ◽  
2000 ◽  
Vol 55 (3) ◽  
pp. 408-413 ◽  
Author(s):  
Scott A MacDiarmid ◽  
Christopher T Harrigan ◽  
Joseph L Cottone ◽  
William J McIntyre ◽  
Don E Johnson
Keyword(s):  
Urethral Stricture ◽  
Balloon Dilation ◽  
Urethral Stricture Disease

Ventral onlay buccal mucosa graft urethroplasty for female urethral stricture

2021 ◽  
Author(s):  
Adem Emrah Coguplugil ◽  
Turgay Ebiloglu ◽  
Selcuk Sarikaya ◽  
Sercan Yilmaz ◽  
Bahadir Topuz ◽  
...  
Keyword(s):  
Urethral Stricture ◽  
Buccal Mucosa ◽  
Buccal Mucosa Graft ◽  
Buccal Mucosa Graft Urethroplasty ◽  
Female Urethral Stricture

Balloon dilation of a urethral stricture caused by a congenital obstructive proximal urethral membrane (COPUM) in a dog

2020 ◽  
Vol 8 (2) ◽  
pp. e001084
Author(s):  
Darren Kelly ◽  
Ingrid Isaac ◽  
Judith Cruzado-Perez ◽  
Florence Juvet
Keyword(s):  
Urethral Stricture ◽  
Balloon Dilation ◽  
Clinical Signs ◽  
Human Beings ◽  
Membranous Structure ◽  
First Report ◽  
Urethral Strictures ◽  
The Future ◽  
History Of ◽  
Proximal Urethra

Congenital urethral strictures are well recognised in human beings and have recently been described in two cats but have not been previously reported in dogs. A 10-month-old female English Bull Terrier presented with a life-long history of being unable to pass a normal stream of urine. Urethrocystoscopy confirmed the presence of a stricture lesion in the proximal urethra. This thin, membranous structure was effaced under endoscopic visualisation using a 10 mm diameter balloon-dilation catheter. Complete and sustained resolution of clinical signs occurred after a single dilation procedure. To the best of our knowledge, this is the first report of a congenital urethral stricture in a dog and the term congenital obstructive proximal urethral membrane may be useful for describing these lesions in the future.

scholarly journals A drug-coated balloon treatment for urethral stricture disease: Two-year results from the ROBUST I study

2020 ◽  
Vol 15 (2) ◽  
Author(s):  
Rachel A. Mann ◽  
Ramon Virasoro ◽  
Jessica M. DeLong ◽  
Rafael E. Estrella ◽  
Merycarla Pichardo ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Adverse Events ◽  
Urethral Stricture ◽  
Flow Rate ◽  
Erectile Function ◽  
Urine Volume ◽  
Urethral Stricture Disease ◽  
Residual Urine ◽  
Drug Coated Balloon

Introduction: Mechanical balloon dilation and direct visualization internal urethrotomy (DVIU) are the most widely used treatments for urethral stricture disease in the U.S., but recurrence rates are high, especially after re-treatment. This study investigates the safety and efficacy of the Optilume™ paclitaxel-coated balloon for the treatment of recurrent strictures. Methods: Men with recurrent bulbar strictures ≤2 cm with 1–4 prior endoscopic treatments were treated with the Optilume™ drug-coated balloon. Patients were evaluated within 14 days, three, six, 12, and 24 months post-treatment. The primary safety endpoint was serious urinary adverse events. The primary efficacy endpoint was ≥50% improvement in International Prostate Symptom Score (IPSS) at 24 months. Secondary outcomes included quality of life, erectile function, flow rate, and post-void residual urine volume. Results: A total of 53 subjects were enrolled and treated; 46 completed the 24-month followup. Forty-three percent of men had undergone >1 previous dilations, with a mean of 1.7 prior dilations. There were no serious adverse events related to treatment at two years. Success was achieved in 32/46 (70%), and baseline IPSS improved from a mean of 25.2 to 6.9 at 24 months (p<0.0001). Quality of life, flow rate, and post-void residual urine volumes improved significantly from baseline. There was no impact on erectile function. Conclusions: Two-year data indicates the Optilume™ paclitaxel-coated balloon is safe for the treatment of recurrent bulbar urethral strictures. Early efficacy results are encouraging and support further followup of these men through five years, as well as further investigation with a randomized trial.

The early and midterm outcomes of ventral only buccal mucosal graft substitution urethroplasty for female urethral stricture

2017 ◽  
Vol 16 (3) ◽  
pp. e1772
Author(s):  
B. Mukhtar ◽  
M. Spilotros ◽  
J. Fairbanks ◽  
M. Pakzad ◽  
R. Hamid ◽  
...  
Keyword(s):  
Urethral Stricture ◽  
Buccal Mucosal Graft ◽  
Female Urethral Stricture

Dorsal onlay buccal mucosal graft urethroplasty in female urethral stricture disease: a single-center experience

2013 ◽  
Vol 25 (4) ◽  
pp. 525-530 ◽  
Author(s):  
Apul Goel ◽  
Sagorika Paul ◽  
Divakar Dalela ◽  
Pushpalata Sankhwar ◽  
Satya Narayan Sankhwar ◽  
...  
Keyword(s):  
Urethral Stricture ◽  
Single Center ◽  
Urethral Stricture Disease ◽  
Single Center Experience ◽  
Buccal Mucosal Graft ◽  
Dorsal Onlay ◽  
Female Urethral Stricture
Sign in / Sign up

Export Citation Format

Share Document